Kwan-young Jung

Daejeon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer Treatment.

Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer Treatment.

Journal: Journal of medicinal chemistry

Published: March 20, 2026

Comparative crystal structure analysis of the human EP300 and CBP KIX domains.

Comparative crystal structure analysis of the human EP300 and CBP KIX domains.

Journal: Biochemical and biophysical research communications

Published: November 15, 2024

Endosulfine alpha maintains spindle pole integrity by recruiting Aurora A during mitosis.

Endosulfine alpha maintains spindle pole integrity by recruiting Aurora A during mitosis.

Journal: BMC cancer

Published: September 22, 2023

Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma.

Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: September 07, 2023

Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.

Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.

Journal: Scientific reports

Published: March 23, 2023

PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia.

PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia.

Journal: Frontiers in molecular biosciences

Published: October 17, 2022

Discovery of BET specific bromodomain inhibitors with a novel scaffold.

Discovery of BET specific bromodomain inhibitors with a novel scaffold.

Journal: Bioorganic & medicinal chemistry

Published: June 24, 2022

PCW-1001, a Novel Pyrazole Derivative, Exerts Antitumor and Radio-Sensitizing Activities in Breast Cancer.

PCW-1001, a Novel Pyrazole Derivative, Exerts Antitumor and Radio-Sensitizing Activities in Breast Cancer.

Journal: Frontiers in oncology

Published: December 14, 2021

Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes.

Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 14, 2021

Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.

Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.

Journal: Molecules (Basel, Switzerland)

Published: February 18, 2021

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.

Journal: Oncology letters

Published: August 10, 2020

MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer.

MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer.

Journal: Frontiers in oncology

Published: June 11, 2020

Showing 1-12 of 29

Last Updated: 09/26/2026